The bradykinin receptor B1R is overexpressed in many human cancers where it might be used as a general target for cancer imaging. In this study, we evaluated the feasibility of using radiolabeled kallidin derivatives to visualize B1R 
INTRODUCTION
The bradykinin receptor family is constituted of two subtypes, B1 and B2, which are involved in the response to tissue damage and are important mediators of pain and inflammation. These G-protein-coupled receptors bind bradykinin and kallidin, which are produced by enzymatic cleavage of kininogens (1) . The overexpression of the B1 and B2 receptors (B1R and B2R) has been documented in many cancers (2) . While B2R is ubiquitously expressed, B1R has low endogenous expression in normal tissues. Molina et al. showed that B1R was expressed in a high proportion of ductal breast carcinomas in situ as well as invasive ductal breast carcinomas (3) . Increased B1R expression was also noted in prostate carcinomas (4) . Activation of B1R and/or B2R has been reported to promote the phosphorylation of extracellular regulated kinases (3), upregulate matrix metalloproteinases (5) , and stimulate cell invasion and metastasis (6, 7) . Crosslinked dimers of bradykinin analogs have also been proposed as therapeutic agents for prostate cancer and small cell lung cancers (8, 9) .
Due to low expression in normal tissues, B1R is an attractive target for the development of imaging probes to visualize B1R positive (B1R+) tumors. Author Manuscript Published OnlineFirst on December 8, 2014 ; DOI: 10.1158/0008-5472.CAN- and flow cytometry (10, 11) , there have been so far few successful attempts to visualize B1R expressing tissues non-invasively, in vivo. Stahl et al. described a 99m Tc labeled peptide (HOE 140) to visualize B2R expression, and evaluated the biodistribution of this compound in healthy mice (12) . Fuchs et al. reported the visualization of chronic cutaneous delayed type hypersensitivity reaction in mice using a 11 C-labelled sulfonamide targeting B1R, but high, non displaceable background activity was observed with the radiotracer (13) . The purpose of this study was to develop and evaluate radiolabeled peptides to noninvasively visualize B1R expression in vivo.
MATERIALS AND METHODS
All chemicals and solvents were obtained from commercial sources, and used without further purification.
Peptide synthesis
B1R targeting peptides were synthesized on solid phase and the methods are further described in the supplementary data section. A semi-preparative (Phenomenex C18, 5µ, 250×10 mm) and an analytical column (Eclipse XOB-C18, 5µ, 150×4 mm) were used for HPLC purification and analysis. To obtain gallium conjugates, a solution of the DOTA-conjugated peptide (4 µmol) and GaCl 3 (20 µmol) in 500 µL sodium acetate buffer (0.1 M, pH 4.0) was incubated at 80 °C for 15 min. The methods for conjugation with non radioactive gallium are described in the supplementary data section. We 
Radiochemistry
An Eckert & Ziegler IGG100 68 Ga generator was used to obtain 68 Ga.
Radioactivity of 68
Ga-labeled peptides was measured using a Capintec CRC-25R/W dose calibrator. The
68
Ga generator was eluted with a total of 4 mL of 0.1 M HCl. The elution which contained the activity was mixed with 2 mL concentrated HCl. The mixture was passed through a DGA resin column and the column was washed by 3 mL 5 M HCl. After the column was dried by passage of air, 68 Ga was eluted off with 0.5 mL water. The purified 68 Ga solution was added to a 4-mL glass vial preloaded with 0.7 mL of HEPES buffer (2 M, pH 5.0) and the DOTA-conjugated precursor. All labeling procedures were performed in a conventional microwave oven, using a 1-minute reaction time. Microwave labeling was used due to previous experience achieving high yields in a short time using similar peptides -it is likely that similar results can be obtained with conventional heating. This step was followed by HPLC purification to ensure high specific activity for preclinical 
Receptor binding assays
The affinity of the peptides for B1R was measured using competitive binding The successful transduction of B1R was also measured by a saturation assay on B1R+ HEK293T cell membranes. Briefly, the cells were disrupted using a Dounce homogenizer, and cell membranes were isolated by sequential centrifugation. Protein concentration was determined using a Bradford assay. 50 μg of membrane protein per well was used for the saturation assay. The assay conditions were similar to the competitive binding assays with the exception that progressively higher concentrations of radioactive [ Mice (n = 4 to 7 per group) were injected with either 0.37 MBq or 3.7 MBq of 68 Ga-labeled peptides, depending on whether the mice were used solely for biodistribution or for imaging followed by biodistribution. For blocking experiments, the radioactive compound was co-injected with 100 μg of the same non-radioactive (e.g. nat Ga) compound. After 60 minutes of uptake, the mice were anesthetized by isoflurane inhalation, then euthanized by CO 2 inhalation. Blood was promptly withdrawn, and the organs of interest were harvested, rinsed with normal saline, blotted dry and inserted into pre-weighted tubes. The tubes were weighed again to obtain the exact organ weight. The radioactivity of the collected mouse tissues was counted using a Cobra II gamma counter (Packard), normalized to the injected dose using a standard curve and expressed as the percentage of the injected dose per gram of tissue (%ID/g).
Preclinical imaging
PET imaging experiments were conducted using a Siemens Inveon microPET/CT scanner. Mice bearing B1R+ and B1R-tumors, as described above, were used for the experiments. In some mice, dynamic scanning was performed to determine the time-activity course of the radiopharmaceuticals in organs of interest. The mice were sedated with 2% isoflurane inhalation and positioned in the scanner. A baseline CT scan was obtained for localization and attenuation correction prior to radiotracer injection, using 60 kV x-rays at 500 μA, 3 sequential bed position with 33% overlap and 220 degree continuous rotation. The mice were kept warm by a heating pad during acquisition. The dynamic acquisition of 60 minutes was started at the time of i.v. injection with 3.7 MBq of 68 Ga-labeled peptide, with or without the presence of 100 µg of excess unlabeled nat Ga-peptide. The list mode data was rebinned into time intervals (12×10 sec, 6×30 sec, 5×60 sec, 6×300 sec, 2×600 sec) to obtain tissue time-activity curves. As we noticed higher renal accumulation and lower urinary excretion in these mice due to the effects of prolonged isoflurane sedation, these animals were not used for biodistribution experiments or for the final analysis of tumor uptake by imaging at 60 minutes. Static imaging was done in the other mice. The mice were briefly sedated for i.v. injection of the radiotracer, then allowed to recover and roam freely in their cages for 55 minutes. At that point, the mice were sedated with 2% isoflurane inhalation, placed in the scanner, and an attenuation correction CT scan was obtained as described above. A single static emission scan was acquired for 10 minutes.
The mice were euthanized and the organs harvested for biodistribution.
Peptidase inhibition with phosphoramidon or enalaprilat
To determine the effects of peptidase inhibition on radiotracer uptake in target tissues, groups of mice injected with 68 Ga-P03083 were co-injected with either 0.3 mg of phosphoramidon or 0.25 mg of enalaprilat in normal saline. Imaging and/or biodistribution were performed 55-60 minutes later, as described above. 
Statistical analysis
Statistical analysis was performed using the Prism 6 software (GraphPad).
Biodistribution data was analyzed by two-way ANOVA, with the organs of interest as a factor, and the radiotracers with or without peptidase inhibition as a second factor. Tukey's multiple comparison test was used to compare the uptake in the tumors and organs between the following groups: P03083 injected without peptidase inhibition, P03083 injected with enalaprilat, P03083 injected with phosphoramidon, 68 Ga-SH01078 and 68 Ga-P03034. An adjusted p value of less than 0.05 was considered significant.
RESULTS

Radiochemistry and plasma stability
The radiochemistry and plasma stability data is reported in Table 1 . Due to the use of HPLC, all radiopeptides were obtained in good yield, at high specific activities, suitable for use in mice for receptor imaging. The stability tests performed in vitro using mouse plasma showed relatively good stability for all peptides in mouse plasma, with the best results obtained with 68 Ga-SH01078.
Cellular expression of B1R and binding affinity
Following transduction with the hB1R, successful gene transfer from the )-kallidin for those cell membranes were 1.9 ± 0.5 and 1.6 ± 0.2 nM, respectively. By competitive binding assays, the inhibition constant (K i ) of P03083 was 2.6 ± 0.7 nM. The K i of SH01078 and P03034 were 27.8 ± 4.9 nM and 16.0 ± 1.9 nM, respectively.
Biodistribution and imaging
The results of the biodistribution experiments are presented in Figure 2 , and the entire data can be found in Supplementary data. The peptides cleared rapidly by urinary excretion, with accumulation in the bladder and kidneys. No significant uptake was seen in other normal organs, with minimal background activity.
When 68
Ga-P03083 was injected without peptidase inhibitors, tumor uptake was 4-fold higher in the transduced B1R+ compared to the control B1R-tumor. This did not improve significantly when 68 Ga-P03083 was co-injected with enalaprilat. Enalaprilat increased renal uptake of 68 Ga-P03083, but did not improve tumor accumulation. However, when co-injected with phosphoramidon, a significant increase (p < 0.0001) in radiotracer uptake was noted in the B1R+ tumors, with 9-fold higher uptake compared to the B1R-tumors (Figure 3) . Similarly, the metabolically stable peptides ( Ga-P03083 co-injected with phosphoramidon, the average ratios of B1R+ tumor to plasma, B1R+ tumor to muscle and B1R+ to B1R-tumors were 9.2 ± 3.7, 35 ± 3 and 9.2 ± 3.7, respectively. With 68 Ga-SH01078, the average ratios were 5.2 ± 2.3, 28 ± 5 and 4.4 ± 1.0, respectively. Similar results were obtained using a PEG linker, as evidenced by the high tumor-to-background ratios obtained with 68 Ga-P03034.
Thus, while the absolute tumor uptake remained moderate due to rapid renal clearance of the radiolabeled peptides, excellent contrast was achieved using either 68 Ga-P03083 co-injected with phosphoramidon, or with the stable derivatives 68 Ga-SH01078 and 
DISCUSSION
Bradykinin receptors are overexpressed in several human cancers (2) . While B2R is expressed in normal tissues, normal physiological expression of B1R is low (1). Thus, B1R is a potentially attractive target for breast and prostate cancer detection. B1R expression is stimulated by the presence of bradykinin, tumor necrosis factor alpha and interleukin-1β (14) . The soluble receptor of the globular heads of C1q (sgC1qR) has also been shown to induce B1R expression 
in endothelial cells (15) . The cause of B1R overexpression in cancers is not known. The presence of tissue kallikreins (notably kallikrein-2 and kallikrein-3, also known as the prostate specific antigen) might play a role in the overexpression of B1R (4). In particular, kallikrein-2 might release bradykinin locally from low and high-molecular weight kininogens, which could chronically stimulate the overexpression of B1R in cancer cells. Alternatively, the immune system might contribute to enhance B1R expression due to leukocyte infiltration associated with secretion of cytokines.
In this study, we observed that despite the addition of a chelator and radiometal at the N-terminus of [Leu 9 ,desArg 10 ]kallidin, receptor binding affinity was maintained using a short spacer. We also showed that replacing proline and phenylalanine by hydroxyproline and cyclohexylalanine at positions 4 and 6 deteriorated binding affinity to B1R but improved metabolic stability in vitro.
More importantly, we demonstrated that it is possible to visualize noninvasively B1R in vivo, by positron emission tomography.
We found that using the native antagonist sequence did not lead to good tumor visualization, and confirmed that this was due to peptidase activity. In vitro plasma stability assays did not predict such low in vivo stability for 
radiopeptides and improved tumor visualization following phosphoramidon coadministration (16) . Enalaprilat is an inhibitor of the angiotensin conversion enzyme (ACE), while phosphoramidon inhibits endopeptidase 24.11 in addition to being a potent inhibitor of ACE and other peptidases (15) . ACE, carboxypeptidase N and endopeptidase 24.11 have been implicated in the degradation of bradykinin (7, 17). We did not see a statistically significant effect of enalaprilat on tumor accumulation of the antagonist radiopeptides in this study. However, enalaprilat administration led to slightly higher renal accumulation of 68 Ga-P03083. Whether this was caused by the effects of enalaprilat on kidney glomerular filtration rate, or due to a change in the nature of peptide fragments from 68 Ga-P03083 degradation remains uncertain.
Poor tumor uptake of the 68 Ga-P03083, a peptide derived from the native sequence of bradykinin, led us to design radiopeptides, 68 Ga-SH01078 and 68 Ga-P03034, with unnatural amino-acids to improve stability. Despite lower affinity to B1R than P03083, images obtained using these modified peptides had significantly improved tumor uptake and tumor:background ratios when used in the absence of peptidase inhibitors. All three peptides evaluated in this study presented significant renal accumulation. It is known that small peptides are filtered by glomerular filtration, but can be reabsorbed by endocytic receptors in proximal tubular cells, notably megalin. The exact mechanism by which the B1R peptides presented in this study accumulate in the kidneys remain unknown, but likely follow similar mechanisms (18) . In conclusion, we demonstrated in this study that bradykinin receptor imaging was possible using metabolically stable derivatives of [Leu 9 ,desArg 10 ]kallidin, a bradykinin receptor antagonist sequence. Good receptor binding affinities to B1R were observed after the addition of a radiometal chelator at the N-terminus of these peptides. Protection from peptidase activity was critical to achieve good tumor visualization in vivo for non-invasive imaging of B1R expression.
These radiolabeled peptides can readily be translated for non-invasive imaging in human subjects. 68 Ga, a radioisotope that is readily available from a longlived 68 Ge generator, does not require an on-site cyclotron and provides excellent image quality with low radiation exposure.
The causes and significance of B1R expression in human cancers will require further investigations. B1R imaging could be a potential surrogate biomarker of the activity of some tissue kallikreins (notably kallikrein 2), reflect an immune response to cancer cells due to the known relationship between B1R expression and tumor necrosis factor alpha and interleukin-1β, or be intrinsically driven by other cellular processes. Potential clinical applications of B1R imaging peptides in oncology include the early detection of breast and prostate cancers, and the non-invasive assessment of B1R expression to predict potential benefits from drugs targeting this receptor. Provided that renal accumulation can be mitigated or reduced, other potential applications include the possibility of using this receptor for the delivery of peptide-drug conjugates, or for radionuclide therapy, using peptides labeled with therapeutic alpha or beta emitters. 
